Strategies aimed at restoring miR-10a-5p levels or targeting the miR-10a-5p/TFR1/STAT3 axis could potentially enhance anti-tumor immune responses and improve treatment outcomes in HCC patients. The gene discussed is STAT3; the disease is neoplasm.